02:13 PM EST, 11/20/2025 (MT Newswires) -- Revelation Biosciences ( REVB ) said Thursday it is on track to hold a meeting with the US Food and Drug Administration later this year following the submission and acceptance of its end-of-phase 1 meeting package to the regulator.

The meeting will establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury, the company said.